N-Nitrosodi-N-propylamine

CASRN 621-64-7

  • IRIS Summary (PDF) (11 pp, 104 K)
  • Status: N-Nitrosodi-N-propylamine is not being reassessed by IRIS at this time.

Health Hazard Assessments for Effects Other than Cancer


Reference Dose for Oral Exposure (RfD) (PDF) (11 pp, 104 K)
Not assessed under the IRIS Program.

Reference Concentration for Inhalation Exposure (RfC) (PDF) (11 pp, 104 K)
Not assessed under the IRIS Program.

Cancer Assessment


Weight of Evidence for Cancer (PDF) (11 pp, 104 K) last updated: 03/31/1987

WOE Characterization Framework for WOE Characterization
B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (US EPA, 1986)
Basis:
  • Increased tumor incidence at multiple sites in two rodent species and in monkeys administered the compound by various routes
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (11 pp, 104 K)

Oral Slope Factor: 7.0 per mg/kg-day
Drinking Water Unit Risk: 2.0 x10 -4 per µg/L
Extrapolation Method: One-hit
Tumor site(s): Hepatic
Tumor type(s): Hepatocellular carcinomas (Druckrey, 1967; Druckrey et al., 1967)


Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (11 pp, 104 K)

Not Assessed under the IRIS Program.

You will need Adobe Reader to view some of the files on this page. See EPA’s PDF page to learn more.